TL;DR
This review explores how network pharmacology (NP) can unlock the complex mechanisms of Traditional Chinese Medicine (TCM) for treating cardiac diseases. By integrating vast biological data, NP helps identify key active compounds, targets, and pathways, offering a systematic approach to modernize TCM and develop novel cardioprotective therapies.
What Problem Does This Paper Address?
Traditional Chinese Medicine (TCM) has long been recognized for its efficacy in treating various ailments, including cardiac diseases. However, its complex composition, involving multiple active ingredients acting on multiple targets and pathways, has historically made it challenging to understand its precise mechanisms of action from a Western scientific perspective. This lack of clear mechanistic understanding hinders the modernization of TCM and its integration into mainstream clinical practice. This paper addresses this gap by showcasing how network pharmacology, a systems-biology approach, can systematically elucidate these complex interactions and provide a scientific basis for TCM's therapeutic effects in cardioprotection.
Methods
The paper outlines a standardized workflow for network pharmacology analysis, which involves several key steps:
- Target Identification: Identifying potential targets for individual active compounds (monomers) from TCM and collecting known disease-associated targets.
- Network Construction: Building a "drug-target-disease" network by identifying overlapping targets between the drug and the disease. This is followed by protein-protein interaction (PPI) analysis to identify key proteins (hub genes).
- Functional Enrichment Analysis: Utilizing Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses to understand the biological roles and signaling pathways associated with the identified targets.
- Molecular Docking: Performing molecular docking simulations to predict the binding affinity between active compounds and their key targets, providing insights into potential drug-target interactions.
- Experimental Validation: Emphasizing the crucial need for in vitro or in vivo experimental validation to confirm the computational predictions.
The paper also details various databases and software tools used in each step, highlighting both established and specialized resources for TCM research.
Datasets
The paper does not introduce new datasets. Instead, it extensively references and categorizes existing databases crucial for network pharmacology analysis, including:
- TCM Databases with Reported Targets: DrugBank, TCMSP, TCMID, TCMIP, HIT, HERB, TCMGeneDIT, ChEMBL, ETCM, NPASS.
- TCM Databases with Predicted Targets: BATMAN-TCM, SwissTargetPrediction, PharmMapper, SuperPred, SEA.
- Databases for Disease Targets: DisGeNET, GEO, PharmGKB, TTD, GeneCards, OMIM, HPO, MalaCards.
- Tools for Protein-Protein Interaction Analysis: STRING, Cytoscape (with plugins like NetworkAnalyzer, CytoNCA, MCODE, CytoHubba).
- Tools for Molecular Docking: AutoDock Vina, Discovery Studio (DS), Schrödinger.
- Databases for Gene Ontology and KEGG Enrichment: DAVID, Metascape.
Key Insights and Ideas
- TCM's Multi-Target Advantage: Network pharmacology elegantly handles the inherent complexity of TCM, which often involves multiple compounds acting on multiple targets, a stark contrast to the single-target approach of many modern drugs.
- Unveiling Synergistic Effects: NP can reveal synergistic interactions between different compounds within a TCM formula, explaining why a whole formula might be more effective than its isolated components.
- Modernizing TCM: This approach provides a robust framework for scientifically validating TCM's efficacy and elucidating its mechanisms, paving the way for its broader acceptance and integration into modern medicine.
- Identifying Key Pathways: The consistent identification of pathways like PI3K-AKT-mTOR, anti-inflammation, and anti-oxidation across different TCMs for various cardiac conditions highlights common therapeutic strategies.
- Potential for Novel Therapies: The application of NP to cancer-induced cardiac injury is presented as a promising new avenue for research, suggesting TCM could offer novel solutions for this complex condition.
Key Results
The review summarizes findings from numerous studies applying network pharmacology to specific TCMs and their active components for various cardiac diseases. Key insights include:
- Myocardial Infarction (MI): TCMs like Salvia miltiorrhiza (Danshen) and Panax ginseng (Renshen) have shown cardioprotective effects through mechanisms including anti-inflammation, anti-oxidation, and regulation of the PI3K-AKT-mTOR signaling pathway. For instance, salvianolic acid A was found to regulate key genes and inhibit the PI3K-AKT pathway, while tanshinone IIA showed high binding affinity with VEGFA.
- Myocardial Ischemia-Reperfusion Injury (MI/RI): Similar to MI, NP studies indicate that TCMs can mitigate MI/RI by modulating inflammatory responses, oxidative stress, and apoptosis. Ginsenoside Rh2 was shown to reduce MI/RI-induced pyroptosis by downregulating key inflammatory mediators.
- Heart Failure (HF): Network pharmacology identified that compounds from Astragalus membranaceus (Huangqi) and Panax ginseng could treat HF by influencing pathways related to inflammation, apoptosis, and vascular homeostasis, with ginsenosides showing strong binding to mTOR.
- Drug-Induced Cardiotoxicity (DIC): Kaempferol, a component found in ginseng, was identified as a potential agent to protect against DIC by binding to STAT1.
- Diabetic Cardiomyopathy (DCM): The Huangqi-Danshen compound was shown to reduce oxidative stress and improve myocardial damage by inhibiting the AMPK-mTOR pathway.
Limitations and Future Work
The authors acknowledge several limitations of network pharmacology:
- Reliance on Computational Predictions: Many NP findings are based on computational predictions, which can lead to a high rate of false positives due to data inaccuracies or limitations in prediction algorithms. Experimental validation is crucial.
- Inaccurate Efficacy and Toxicity Assessment: NP methods struggle to accurately assess the overall efficacy and toxicological profile of complex TCM formulas, as the effects of decoction processes and synergistic interactions are not fully captured.
- Oversimplification of ADME: Using simplified parameters like oral bioavailability (OB) and drug-likeness (DL) to represent complex Absorption, Distribution, Metabolism, and Excretion (ADME) processes is an oversimplification.
- Low Concentration of Active Components: Some identified "active components" might be present in very low concentrations in raw herbs or biological fluids, potentially failing to reach therapeutic levels.
Future work suggested includes:
- In-depth Exploration of Cancer-Induced Cardiac Injury: Applying NP to investigate novel mechanisms and therapeutic targets for cancer-induced cardiac injury, a condition not yet extensively studied with NP.
- Translational Research: Bridging the gap between NP findings and clinical applications by conducting more rigorous experimental validation.
- Investigating Complex Interactions: Developing more sophisticated computational models to better account for the synergistic effects and dynamic changes in TCM formulations.
Summary updated